2022 NICE 技术鉴定指南：帕博西尼联合氟维司群治疗内分泌治疗后激素受体阳性、HER2阴性晚期乳腺癌 [TA836]

2022-10-26 英国国家卫生与临床优化研究所 NICE官网

关于帕博西尼联合氟维司群治疗内分泌治疗后激素受体阳性、HER2 阴性晚期乳腺癌的循证建议。

中文标题：

英文标题：

Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy Technology appraisal guidance [TA836]

发布机构：

英国国家卫生与临床优化研究所

发布日期：

2022-10-26

简要介绍：

关于帕博西尼联合氟维司群治疗内分泌治疗后激素受体阳性、HER2 阴性晚期乳腺癌的循证建议。

相关资料下载：

GetToolGuiderByIdResponse(projectId=1, id=1d39f1c002e5560f, title=2022 NICE 技术鉴定指南：帕博西尼联合氟维司群治疗内分泌治疗后激素受体阳性、HER2阴性晚期乳腺癌 [TA836], enTitle=Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy Technology appraisal guidance [TA836], guiderFrom=NICE官网, authorId=0, author=, summary=关于帕博西尼联合氟维司群治疗内分泌治疗后激素受体阳性、HER2 阴性晚期乳腺癌的循证建议。, cover=https://img.medsci.cn/Random/doctor-holding-thermometer-closeup-4HFQS9L.jpg, journalId=0, articlesId=null, associationId=2005, associationName=英国国家卫生与临床优化研究所 , associationIntro=英国国家卫生与临床优化研究所 (NICE,National Institute for Health and Clinical Excellence), copyright=0, guiderPublishedTime=Wed Oct 26 00:00:00 CST 2022, originalUrl=, linkOutUrl=, content=<p><span style="color: #000000;">关于帕博西尼联合氟维司群治疗内分泌治疗后激素受体阳性、HER2 阴性晚期乳腺癌的循证建议。</span></p>, tagList=[TagDto(tagId=3456, tagName=晚期乳腺癌), TagDto(tagId=8754, tagName=氟维司群), TagDto(tagId=81638, tagName=帕博西尼)], categoryList=[CategoryDto(categoryId=5, categoryName=肿瘤, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21054, categoryName=梅斯医学-乳腺癌网, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=0, guiderKeyword=, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指南, guiderLanguage=1, guiderRegion=2, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=1748, appHits=11, showAppHits=0, pcHits=165, showPcHits=1737, likes=0, shares=0, comments=0, approvalStatus=1, publishedTime=Wed Nov 02 20:41:00 CST 2022, publishedTimeString=2022-10-26, pcVisible=1, appVisible=1, editorId=0, editor=FUNNYMAN, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=4, createdBy=null, createdName=FUNNYMAN, createdTime=Thu Oct 27 00:08:21 CST 2022, updatedBy=6459136, updatedName=玉在山, updatedTime=Fri Jan 05 21:30:51 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=2022 NICE 技术鉴定指南：帕博西尼联合氟维司群治疗内分泌治疗后激素受体阳性、HER2阴性晚期乳腺癌 [TA836].pdf)])